Genetic Signatures Limited (ASX:GSS – Get Rating) insider Caroline Waldron acquired 16,700 shares of the firm's stock in a transaction on Tuesday, February 28th. The shares were bought at an average cost of A$0.86 ($0.58) per share, with a total value of A$14,311.90 ($9,670.20).
Genetic Signatures Stock Performance
Genetic Signatures Company Profile
(Get Rating)
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name.
Recommended Stories
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Genetic Signatures Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Signatures and related companies with MarketBeat.com's FREE daily email newsletter.
Genetic Signature Limited(ASX：GSS-GET Rating)内部人士Caroline Waldron在2月28日星期二的一次交易中收购了该公司16,700股股票。这些股票的平均价格为每股0.86澳元(合0.58美元)，总价值为14,311.90澳元(合9,670.20美元)。
基因签名股票表现
基因签名公司简介
(获取评级)
Genetic Signature Limited在澳大利亚、亚太地区、美洲、欧洲、中东、以色列和非洲经营分子诊断(MDX)公司。它设计和制造了一套基于实时聚合酶链式反应的产品，用于检测EasyScreen品牌下的传染病。
推荐故事
- 市场回顾周-2/27-3/3
- 升幅最大的3只股票正在逆转
- 如何寻找蓝筹股分红股
- Zscaler，Inc.Plummets，是时候去抄底了吗？
- 什么是好的股息收益率？如何决定
每天收到关于基因签名的新闻和评级-在下面输入您的电子邮件地址，以通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对基因签名和相关公司的评级的每日摘要。
